New research reveals how the combined impact of amyloid-β and tau deposits alters brain activity patterns in older adults, providing key insights into early Alzheimer’s disease progression.

Researchers at Washington University School of Medicine in St. Louis have conducted a longitudinal study on an individual ...

More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...

The factor that tips you over the edge from being at risk for a disease to actually developing the disease is not always ...

A groundbreaking study reveals how a rare combination of genetics, proteomics, and environmental factors may hold the key to ...

gets broken down in the brain into smaller pieces such as amyloid-β, the peptide that notoriously goes on to form the plaques associated with Alzheimer’s. In the ensuing Q&A, another member of the ...

A research team from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has discovered that the two key pathological hallmarks of Alzheimer's—tau protein and beta-amyloid ...

Using a new animal model of Alzheimer’s disease, the study highlights a potential breakthrough in treatment strategies. Unlike current therapies that primarily target a single toxic protein linked to ...

Amyloidosis occurs due to a buildup of amyloid proteins in the body. Along with treatment, complementary therapy can help with symptoms. Some examples include movements, such as yoga, sleep ...

A research team from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has discovered that the two key pathological hallmarks of Alzheimer’s—tau protein and beta-amyloid ...